Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session

232TiP - Early acupuncture treatment of vasomotor symptoms and sleep disorders in Breast Cancer LHRHa induced menopause: AcuFLASH Study

Date

04 May 2022

Session

Poster Display session

Presenters

Alessandra Fabi

Citation

Annals of Oncology (2022) 33 (suppl_3): S224-S231. 10.1016/annonc/annonc895

Authors

A. Fabi1, C. MAGGIORE2, A. Di Micco2, M.M. Rossi2, A. Filippone2, C. Rossi2, L. Forcina2, D. Giannarelli1, R. Masetti1, S. Magno2

Author affiliations

  • 1 Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome/IT
  • 2 Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome/IT

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 232TiP

Background

Debilitating symptoms such as hot flashes and sleep deficiency, due to luteinizing hormone-releasing hormone analogues (LHRHa) induced ovarian suppression in premenopausal Breast Cancer (BC) patients, affect quality of life and adherence to endocrine therapies (ET). Pharmacological options available to improve these conditions are limited and often burdened by significant side effects. Acupuncture can be considered for vasomotor symptoms management according to several clinical trials and guidelines, including The National Comprehensive Cancer Network (NCCN) and ESMO Advanced Breast Cancer (ABC) symptom control Guidelines. The aim of this study is to evaluate the impact of acupuncture in preventing worsening in terms of frequency/severity of hot flashes and sleep disorders in paucysintomatic premenopausal BC patients undergoing LHRHa plus endocrine therapy (tamoxifen or aromatase inhibitors).

Trial design

This is a prospective randomized clinical trial of superiority of acupuncture compared to usual care for prevention/early treatment of vasomotor symptoms and sleep impairment in LHRHa induced amenorrhea. The primary endpoint will be a reduction in frequency and intensity of hot flashes between the intervention arm compared to standard care, measured by the Hot Flash Composite Score (HFCS) at 6 months following the protocol. Among the secondary outcomes, sleep quality will be measured by the Pittsburgh Sleep Quality Index (PSQI) and quality of life by the Menopause-specific Quality of Life Questionnaire (MenQOL) and EORTC Quality of Life Questionnaire (EORTC QLQ-C30). A significant reduction in the outbreak of hot flashes and insomnia in the intervention arm would consolidate an evidence-based integration of acupuncture in the management of BC patients undergoing ET, with lower toxicities compared to pharmacological treatments and improved quality of life.

Legal entity responsible for the study

The authors.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.